CNSP Stock Overview
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
CNS Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.18|
|52 Week High||US$1.55|
|52 Week Low||US$0.17|
|1 Month Change||-27.36%|
|3 Month Change||-31.06%|
|1 Year Change||-87.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-96.06%|
Recent News & Updates
CNS Pharmaceuticals reports Q2 results
CNS Pharmaceuticals press release (NASDAQ:CNSP): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into 2023.
|CNSP||US Pharmaceuticals||US Market|
Return vs Industry: CNSP underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: CNSP underperformed the US Market which returned -23.2% over the past year.
|CNSP Average Weekly Movement||9.7%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CNSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CNSP's weekly volatility (10%) has been stable over the past year.
About the Company
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals Fundamentals Summary
|CNSP fundamental statistics|
Is CNSP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNSP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||0.00%|
How did CNSP perform over the long term?See historical performance and comparison
Is CNSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNSP?
Other financial metrics that can be useful for relative valuation.
|What is CNSP's n/a Ratio?|
Price to Book Ratio vs Peers
How does CNSP's PB Ratio compare to its peers?
|CNSP PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
BMMJ Body and Mind
NBY NovaBay Pharmaceuticals
PALI Palisade Bio
CNSP CNS Pharmaceuticals
Price-To-Book vs Peers: CNSP is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (0.7x).
Price to Earnings Ratio vs Industry
How does CNSP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: CNSP is good value based on its Price-To-Book Ratio (0.6x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is CNSP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CNSP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CNSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CNSP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CNSP's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is CNS Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNSP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNSP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNSP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNSP is forecast to have no revenue next year.
High Growth Revenue: CNSP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNSP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has CNS Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNSP is currently unprofitable.
Growing Profit Margin: CNSP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNSP is unprofitable, and losses have increased over the past 5 years at a rate of 29.8% per year.
Accelerating Growth: Unable to compare CNSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNSP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: CNSP has a negative Return on Equity (-112.46%), as it is currently unprofitable.
Discover strong past performing companies
How is CNS Pharmaceuticals's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CNSP's short term assets ($11.4M) exceed its short term liabilities ($923.9K).
Long Term Liabilities: CNSP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CNSP has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CNSP's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNSP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CNSP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 54.9% each year
Discover healthy companies
What is CNS Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|CNS Pharmaceuticals Dividend Yield vs Market|
|Company (CNS Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (CNS Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate CNSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNSP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CNSP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Climaco (53 yo)
Mr. John Michael Climaco, Esq., J.D serves as Chairman of the Board at CNS Pharmaceuticals, Inc. Mr. Climaco has been the Chief Executive Officer of CNS Pharmaceuticals, Inc. since September 2017 and serve...
CEO Compensation Analysis
|John Climaco's Compensation vs CNS Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$846k||US$525k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$440k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$1m||US$214k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$164k||US$150k|
|Dec 31 2017||US$140k||US$50k|
Compensation vs Market: John's total compensation ($USD845.94K) is about average for companies of similar size in the US market ($USD781.86K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: CNSP's management team is considered experienced (3.3 years average tenure).
Experienced Board: CNSP's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|06 Dec 21||BuyUS$4,702||Christopher Downs||Individual||5,000||US$0.94|
|19 Nov 21||BuyUS$5,192||Christopher Downs||Individual||4,500||US$1.15|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
CNS Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: CNS Pharmaceuticals, Inc.
- Ticker: CNSP
- Exchange: NasdaqCM
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.206m
- Shares outstanding: 40.03m
- Website: https://www.cnspharma.com
Number of Employees
- CNS Pharmaceuticals, Inc.
- 2100 West Loop South
- Suite 900
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CNSP||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.